**Abstract**

**Ensuring safety in prescribing practice: Immunotherapy treatment and how to manage side effects**

Laura Collantes-Espinosa Msc PgDip Bsc RN

I currently work as an Advanced Nurse Practitioner (ANP) at the Royal Marsden NHS Trust in the Private Systemic Anticancer Treatment (SACT) clinic. I provide care to patients undergoing SACT for different tumour groups such as breast, GI, gynae and neurology.

I have experience as a Lecturer Practitioner in Advance Practice, SACT and Acute Oncology (AOS). I worked as an ANP in AOS at Imperial College Healthcare Trust.

Having experience in oncology, haematology, palliative care ad AOS has allowed me to expand my nursing skills and it has given me a broader overview in cancer care which allowed me to efficiently practice as an ANP.

My qualifications are as follows:

- PgDip in Advanced Practice by King’s College London (2016)

- Master in Medical Expertise by Universidad Complutense de Madrid (2011)

- Nursing Degree by Universidad Complutense de Madrid (2007)

This presentation gives a brief overview of the current immune checkpoint inhibitors used in practice and their uses and what considerations are required when prescribing them. We will explore the most common adverse events and discuss their treatment through two real life case studies.

Reference list:

* Centanni M.,
* [Moes](https://pubmed.ncbi.nlm.nih.gov/?term=Moes%20DJ%5BAuthor%5D)
* [D.J.A.](https://pubmed.ncbi.nlm.nih.gov/?term=Moes%20DJ%5BAuthor%5D)
* [R.](https://pubmed.ncbi.nlm.nih.gov/?term=Moes%20DJ%5BAuthor%5D),[Trocóniz](https://pubmed.ncbi.nlm.nih.gov/?term=Troc%C3%B3niz%20IF%5BAuthor%5D)
* I.F.,[Ciccolini](https://pubmed.ncbi.nlm.nih.gov/?term=Ciccolini%20J%5BAuthor%5D)
* [J](https://pubmed.ncbi.nlm.nih.gov/?term=Ciccolini%20J%5BAuthor%5D).
* and
* [Coen van Hasselt](https://pubmed.ncbi.nlm.nih.gov/?term=van%20Hasselt%20JG%5BAuthor%5D)
* [J.](https://pubmed.ncbi.nlm.nih.gov/?term=van%20Hasselt%20JG%5BAuthor%5D)
* [G.](https://pubmed.ncbi.nlm.nih.gov/?term=van%20Hasselt%20JG%5BAuthor%5D) (2019)
* *Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors*.
* Clinical Pharmacokinetics 58(7): 835–857..
* Available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584248/>
* *Fearfield L., Heelan K., Harland C., Larkin J., Turajlic S., Chauhan D. And Yousaf N. (2019) Immune*
* *Checkpoint Inhibitor (Icpi)-related Toxicity: Management Of Skin Rash/Toxicity Available at RMH intranet*
* *Haanen J., Obeid M., Spain L. , Carbonnel F. , Wang Y. , Robert C., Lyon A. R. , Wick W., Kostine*
* *M., Peters S. , Jordan K.  & Larkin J. , on behalf of the ESMO Guidelines Committee (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up*
* Available online at
* <https://www.esmo.org/guidelines>
* Haanen J., Lugowska I., Garassino M.C., Califano R. (2018)
* *ESMO Handbook of Immuno-Oncology available at* [*https://oncologypro.esmo.org/education-library/esmo-handbooks/*](https://oncologypro.esmo.org/education-library/esmo-handbooks/)
* Khan O.F and Monzon  J.
* *(2020) Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.*
* Current oncology
* 27(Suppl 2): S43–S50.
* Available at [*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194002/*](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194002/)
* Spain L., Yousaf  N. And Hunter N. (2017)
* *Immune Checkpoint Inhibitor (Icpi)-related Toxicity: Supportive Management Of Patients*
* *On High Dose Steroids* Available At Rmh Intranet
* Spain L., Yousaf  N., Turajilic S., Yousaf N., Larkin J., Powell N., Riley U.
* And Chauhan D. (2019) *Immune Checkpoint Inhibitor (Icpi)-related Toxicity: Management Of*
* *Diarrhoea & Colitis* Available At Rmh Intranet
* U.S.  Department of Health and Human services (2017)
* *Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0* available
* at [Common](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf)
* [Terminology Criteria for Adverse Events (CTCAE) (cancer.gov)](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf)
* [Wojtukiewicz](https://pubmed.ncbi.nlm.nih.gov/?term=Wojtukiewicz%20MZ%5BAuthor%5D)
* M.Z.,
* [Rek](https://pubmed.ncbi.nlm.nih.gov/?term=Rek%20MM%5BAuthor%5D) M.M.,[Karpowicz](https://pubmed.ncbi.nlm.nih.gov/?term=Karpowicz%20K%5BAuthor%5D)
* K.,
* [Górska](https://pubmed.ncbi.nlm.nih.gov/?term=G%C3%B3rska%20M%5BAuthor%5D) M.,[Polityńska](https://pubmed.ncbi.nlm.nih.gov/?term=Polity%C5%84ska%20B%5BAuthor%5D)
* B.,[Wojtukiewicz](https://pubmed.ncbi.nlm.nih.gov/?term=Wojtukiewicz%20AM%5BAuthor%5D)
* A.M.,[Moniuszko](https://pubmed.ncbi.nlm.nih.gov/?term=Moniuszko%20M%5BAuthor%5D)
* M. [Radziwon](https://pubmed.ncbi.nlm.nih.gov/?term=Radziwon%20P%5BAuthor%5D)
* P.,[Tucker](https://pubmed.ncbi.nlm.nih.gov/?term=Tucker%20SC%5BAuthor%5D)
* S.T.,and [Honn](https://pubmed.ncbi.nlm.nih.gov/?term=Honn%20KV%5BAuthor%5D)
* K.V. (2021) *Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge*
* *for internists and general practitioners.* Cancer metastasis Rev.  40(3): 949–982. Available at
* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556173/>